Cancer-focused drugmaker BeyondSpring Pharmaceuticals is reducing its U.S. workforce by 35 percent.

The reorganization follows the company’s Nov. 30 Complete Response Letter from the FDA for its new drug application (NDA) for plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia (CIN).

BeyondSpring said it will continue the regulatory process for plinabulin for the indication in China and the U.S., and a separate NDA for non-small cell lung cancer.

As part of its reorganization, the company said it will move some of its employees to its subsidiaries.